Moleculin Biotech (MBRX)

• Market cap: $12.9M
• 1 day: -0.24%
• 5 days: -8.93%
• 1 month: 7.18%
• 3 months: -66.34%
• 6 months: -75.63%
• Year to date: 15.47%
• 1 year: -86.41%
• 5 years: -99.77%
• 10 years: -99.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Employees: 17